Cantabio Pharmaceuticals to Present Results from its Tau Protein Targeting Therapeutic Program for the treatment of Alzheimer’s Disease at the Advances in Alzheimer’s and Parkinson’s Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy
SAN FRANCISCO, CA–(Marketwired – February 26, 2018) – Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s and other related neurodegenerative diseases, today announced that Dr. Gergely Tóth, Cantabio’s CEO, will present results of the company’s Tau protein targeting small molecule pharmacological chaperone therapeutic program at the Advances in Alzheimer’s and Parkinson’s Therapies, An AAT-AD/PD Focus Meeting in Torino, Italy, March 15 – 18, 2018.
Aggregation of the Tau protein is linked to the onset and progression Alzheimer’s disease (AD) and other Tauopathies, a subset of neurodegenerative disorders, including AD and frontotemporal dementias. Tau is one of the most recognized targets for the potential treatment of AD.
The presentations will describe the positive biological activity in cellular and in an in vivo model of AD of one of Cantabio’s novel Tau protein targeting small molecule drug candidate including:
Significant alleviation of movement deficit in a genetically modified, human Tau over-expressing fly in its motor neurons, an in vivo disease AD model.
Significant reduction of the formation of Tau aggregates in vitro and in Tau over-expressing N2a neublastoma cells.
Strong target engagement of the small molecule drug candidate to the Tau protein demonstrated by high affinity binding data in vitro.
The data will be presented on:
March 15, 8:00 -18:00 CET – B2.g Therapeutic Targets, Mechanisms for Treatment: protein aggregation, NFT, misfolding, chaperones; Abstract Number 074
The poster titled, “Novel Small Molecule Tau Aggregation Inhibitor Alleviates Tau caused Deficits in Cell and Fly Models of Tauopathy”.
The presentations are co-authored by researchers from the University of Cambridge (UK) and CAESAR Research Center, MPG (Germany).
Cantabio’s CEO, Gergely Toth said: “We are excited to share new results from our Tau protein targeting pharmacological chaperone program at the Advances in Alzheimer’s and Parkinson’s Therapies meeting. These, combined with the results we are presenting on our DJ-1 program, show that Cantabio’s portfolio of therapeutic programs continue to make significant progress towards clinical trials, and confirm the effectiveness of our overall strategic approach. The presented results from our CB301 Tau targeting program provide evidence of efficacy of one of our small molecule drug candidates in multiple level models of Tauopathies, further demonstrating its potential as a disease modifying therapeutic candidate for Alzheimer’s disease. This is further confirmation of the potential of our approach of tackling the disease at its source by preventing the formation of the toxic aggregates that are considered a root cause of the disease.”
Cantabio is focused on bringing novel, first in class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s and Parkinson’s, and oxidative stress. More information is available at www.cantabio.com.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Thomas Sawyer, Ph.D., M.B.A.
Cantabio Pharmaceuticals, Inc.
Investors and Media Relations: